Incentives Targeting Gestational Weight Gain in Overweight/Obese Low Income Women

Overview

Excessive weight gain during pregnancy, particularly in overweight and obese women, predisposes to adverse perinatal outcomes and has long term effects on maternal and neonatal health. With an inverse relationship between socioeconomic status and obesity, significant health disparities exist between obese and normal weight women. The Institute of Medicine (IOM) recently revised its gestational weight gain recommendations, targeted to pregravid body mass index (BMI), to minimize pregnancy complications. However, these recommendations are based on cross sectional observational studies and neither the ideal method to achieve weight gain goals nor whether perinatal outcome is optimized with active management of weight gain is known. The investigators propose to investigate a behavioral incentive-based intervention to improve compliance with IOM weight gain recommendations during pregnancy in low-income overweight and obese women. The investigators will evaluate if 1) gestational weight gain can be reliably targeted to the IOM recommendations and 2) active weight gain management during pregnancy improves perinatal outcomes. Two study groups will be compared in a prospective randomized trial; 1) those receiving standard obstetrical care and 2) those receiving behavioral weight management counseling plus financial incentives for achieving weight gain goals. The main outcome measure will be the percentage of women gaining within the IOM recommendations based on prepregnancy BMI. Secondary outcomes evaluated will include fetal growth and body composition changes, birth weight and the rate of cesarean delivery. The investigators hypothesize that 1) the behavioral intervention with incentives will result in greater compliance to IOM guidelines for gestational weight gain than standard care and 2) targeting weight gain to the IOM guidelines will lead to a reduction in the rates of fetal macrosomia and cesarean delivery. Finally, cost effectiveness of treatment conditions will be examined. This intervention, if efficacious and cost-effective, has the potential to improve compliance with gestational weight gain guidelines, optimize perinatal outcomes, and reduce health disparities.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)
  • Study Primary Completion Date: August 28, 2017

Interventions

  • Behavioral: Financial incentives
    • Participants receive a behavioral intervention and financial incentives for meeting gestational weight gain goals.

Arms, Groups and Cohorts

  • Experimental: Behavioral, incentives
    • Participants receive behavioral intervention and financial incentives for meeting gestational weight gain goals
  • No Intervention: Standard care
    • Participants receive standard obstetrical care from their provider

Clinical Trial Outcome Measures

Primary Measures

  • Gestational weight gain within the Institute of Medicine guidelines
    • Time Frame: At time of delivery
    • Total gestational weight gain at time of last prenatal visit. For participants in the intervention arm, gestational weight gain at 2 week intervals will also be assessed.

Secondary Measures

  • Cesarean delivery rate
    • Time Frame: Time of delivery
    • Cesarean delivery rate (as a percent of total deliveries) will be assessed
  • Fetal macrosomia
    • Time Frame: At delivery
    • Fetal weight at delivery will be recorded. Percent fetal macrosomia (birthweight >4000g) will be assessed.

Participating in This Clinical Trial

Inclusion Criteria

-≥18 years of age and ≤ 45 years of age -≤16 weeks gestation

  • BMI ≥25 – Ultrasound documented viable singleton intrauterine pregnancy – English speaking – Planning to deliver at Fletcher Allen Health Care – Willing to be randomized to one of the study groups – Written informed consent Exclusion Criteria:

  • Major fetal congenital or chromosomal anomaly – Women with a restricted diet (i.e., celiac disease, prior bariatric surgery, Phenylketonuria, or other metabolic disorder)

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: 45 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Vermont
  • Collaborator
    • National Institute of General Medical Sciences (NIGMS)
  • Provider of Information About this Clinical Study
    • Principal Investigator: Julie Phillips, Project Director – University of Vermont

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.